Toward a treaty on safety and cost-effectiveness of pharmaceuticals and medical devices: Enhancing an endangered global public good

Globalization and Health

Volumn 2, Issue , 2006, Pages

  Faunce, Thomas Alured ^a,b  

^a The Australian National University   (Australia)

^b Regulatory Institutions Network   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; NON PRESCRIPTION DRUG;

ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; BUDGET; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; ECONOMIC EVALUATION; GOVERNMENT REGULATION; HEALTH CARE ACCESS; HEALTH CARE MANAGEMENT; HEALTH CARE POLICY; HEALTH CARE QUALITY; INTERNATIONAL COOPERATION; INVESTMENT; MEDICAL INSTRUMENTATION; MEDICARE; PHARMACEUTICAL CARE; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROFIT; PUBLIC HEALTH; QUALITY ADJUSTED LIFE YEAR; RISK MANAGEMENT; TREATMENT OUTCOME;

EID: 33746444923     PISSN: 17448603     EISSN: None     Source Type: Journal    
DOI: 10.1186/1744-8603-2-5     Document Type: Article

References (78)

1. Faunce TA: 'Global Intellectual Property Protection for Innovative Pharmaceuticals: Challenges for Bioethics and Health Law'. In Glabolisation and Health Edited by: Bennett B, Tomossy GF. Springer. Dordrecht; 2005.
2. Moghimi SM, Hunter AC, Murray JC: 'Nanomedicine: Current Status and Future Prospects'. FASEB Journal 2005, 19:311-330.
3. Neumann PJ, Rosen AB, Weinstein MC: 'Medicare and Cost-Effectiveness Analysis'. New England Journal of Medicine 2005, 353(14):1516-1522.
4. Berger, et al.: Health Care Cost, Quality and Outcomes. International Society for Pharmacoeconomics and Outcomes Research, Lawrenceville NJ; 2003.
5. Berger, et al.: Health Care Cost, Quality and Outcomes. International Society for Pharmacoeconomics and Outcomes Research, Lawrenceville NJ. European Economic Community, Medical Device Directive Council Directive 93/42/EEC; 2003. 14 June 1993
6. Berger, et al.: Health Care Cost, Quality and Outcomes. International Society for Pharmacoeconomics and Outcomes Research, Lawrenceville NJ; 2003.
7. Henry DA, Hill SR, Harris A: Drug prices and value for money. The Australian Pharmaceutical Benefits Scheme'. Journal of the American Medical Association 2005, 294(2):2630-2632.
8. Pammolli F, et al.: Medical devices Competitiveness and Impact on Public Health Expenditure. Directorate Entreprise of the European Commission University of Florence 2005.
9. Ray WA, Stein CM: 'Reform of drug regulation-Beyond an Independent Drug-Safety Board'. New England Journal of Medicine 2006, 354(2):194-201.
10. Global Harmonization Task Force: Working Towards Harmonization in Medical Device Regulation. 2006 [http://www.ghtf.org/]. (last accessed 2 March 2006)
11. Bloor K, Maynard A: 'Cost-Effective Prescribing of Pharmaceuticals: The Search for the Holy Grail,'. In Purchasing and Providing Cost-Effective Health Care Edited by: Drummond MF, Maynard A. London: Churchill Livingstone; 1993.
12. Birkett DJ, Mitchell AS, McManus P: A Cost-Effectiveness Approach to Drug Subsidy and Pricing in Australia. Health Affairs 2001, 20(3):104-114.
13. Day RO, Birkett DJ, Miners J, Shenfield GM, Henry DA, Seale JP: 'Access to medicines and high-quaiity therapeutics: global responsibilities for clinical pharmacology. Medical Journal of Australia 2005, 182(7):322-323.
14. Australian Government Department of Health and Ageing: National Medicines Policy. [http://www.health.gov.au/internet/wcms/ publishing.nsf/Content/nmp-objectives-policy.htm]. (last accessed 4 Sept 2005)
15. Interviews by the author with PBAC members in. 2005.
16. New Zealand Pharmaceutical Management Agency 2005 [http://www.pharmac.govt.nz/who are pharmac.asp]. last accessed 12 Dec 2005
17. Detsky A: 'Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada.'. Pharmacoeconomics 1993, 3(5):354-61.
18. Morgan S, Bassett K, Mintzes B: Outcomes-Based Drug Coverage in British Columbia'. Health Affairs 2004, 23(3):269-276.
19. Canadian Coordinating Office for Health Technology Assessment Interviews by the author with CEDAC officials in 2005 [https:/.www.ccohta.ca/CDR/ cdr_committeese.cfm]. last accessed 12 Dec 2005.
20. Canadian Patented Medicines Prices Review Board 2005 [http://www.pmprb-cepmb.gc.ca/english/view.asp?x=272#2]. last accessed 12 Dec 2005
21. Interviews by the author with PMPRB senior officials in Ottawa. 2005.
22. European Medicines Agency website 2005 [http://www.emea.eu.int/ sitemap.htm]. (last accessed 8 March 2006)
23. Dickson J, Hurst J, Jacobzone S: Survey of pharmacoeconomic assessment activity in eleven countries. Directorate for Employment labor and Social Affairs, OECD Health Working Papers No4, Organisation for Economic Co-Operation and Development 2003.
24. Taylor RS, Drummond MF, Salkeld G, Sullivan SD: 'Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle'. British Medical Journal 2004, 329:972-975.
25. Kincses G: 'The situation of health technology assessment in Hungary.' Poster presentation, International Society for Pharmacoeconomics and Outcomes Research 2nd Asia-Pacific Conference Shanghai. 2004. 6 March 2006
26. Giuliani G, Selke G, Garattini L: The German Experience in Reference Pricing Health Policy. 1998, 44(1):73-85.
27. Berger ML: 'Cost-Effectiveness Analysis. From Science to Application'. Medical Care 2005, 43(7):49-53.
28. Lipsy RJ: 'Institutional formularies: the relevance of pharmacoeconomic analysis to formulary decisions. Pharmacoeconomics 1992, 1(4):265-81.
29. The PPRS sets each such company a set level of return on capital, which represents the amount that can be earned through sales to the National Health Service. Return on capital is calculated from 21% of a fixed asset figure in a submitted annual financial return, also taking into account the company's expenditure on research and development marketing and provision of information. United Kingdom Pharmaceutical Price Regulation Scheme [http://www.dh.gov.uk/PolicyAndGuidance/MedicinesPhar macyAndIndustry/PharmaceuticalPriceRegulationScheme/ThePPRSS cheme/fs/ en]. last accessed 12 Dec 2005
30. National Institute for Health and Clinical Excellence [http://www.nice.org.uk/page.aspx?o=home].last accessed 12 Dec 2005
31. Henry DA, Hill SR, Harris A: 'Drug Prices and Value for Money. The Australian Pharmaceutical Benefits Scheme'. Journal of the American Medical Association 2005, 294(20):2630-2632.
32. US Food and Drug Administratioj. Risk Management [http://www.fda.gov/oc/ mcclellan/riskmngt.html]. (last accessed 8 Feb 2006)
33. Luce BR: 'What will it take to make cost-effectiveness analysis acceptable in the United States?'. Medical Care 2005, 43(7):44-48.
34. Kamae I: 'Health economics in Japan: Dawning or Staggering?'. International Society for Pharmacoeconomics and Outcomes Research 2nd Asia-Pacific Conference Shanghai. 6 March 2006
35. Drummond M, Sculpher M: 'Common methodological flaws in economic evaluations'. Medical Care 2005, 43(7):11-5-14.
36. Soumerai SB: A critical analysis of studies of state drug reimbursement policies: research in need of discipline. Millbank Quarterly 1993, 71(2):217-252.
37. Neumann PJ: 'Evidence-based and value-based formulary guidelines'. Health Affairs 2004, 23:124-34.
38. Neumann P: 'Evidence-based policy and benefit design for health care value'. International Society for Phormacoeconomics and Outcomes Research 2nd Asia-Pacific Conference Shanghai. 6 March 2006.
39. Berger ML: Cost-effectiveness analysis. From science to application. Medical Care 2005, 43(7):1149-53.
40. Aspinall SL, Good CB, Glassman PA, Valentino MA: 'The evolving use of cost-effectiveness analysis in formulary management within the department of veterans affairs'. Medical Care 2005, 43(7):20-26.
41. Hu S: 'Pharmacoeconomics and outcome research in China'. International Society for Pharmacoeconomics and Outcomes Research 2nd Asia-Pacific Conference Shanghai. 6 March 2006
42. Yang B-M: 'Use of economic evaluation in insurance decision making: South Korea'. International Society for Pharmacoeconomics and Outcomes Research 2nd Asia-Pacific Conference Shanghai. 6 March 2006
43. Chuen LS: 'Recent changes in the healthcare scene in Singapore'. International Society for Pharmacoeconomics and Outcomes Research 2nd Asia-Pacific Conference Shanghai. 6 March 2006
44. Tangcharoensa V: 'Role of pharmaco-economic in Thailand'. International Society for Pharmocoeconomics and Outcomes Research 2nd Asia-Pacific Conference Shanghai. 6 March 2006
45. Hameed A, Aljunid SM: 'Pharmaco-economics and outcomes research in Pakistan"Pharmaco-economics and outcomes research in Malaysia'. International Society for Pharmacoeconomics and Outcomes Research 2nd Asia-Pacific Conference Shanghai. 6 March 2006
46. WHO: The World Medicines Situation Geneva. World Health Organisation; 2004.
47. Danzon PM, Towse A: Theory and implementation of differential pricing of pharmaceuticals. In International Public Goods and Transfer of Technology Under a Globalised Intellectual Property Regime Edited by: Maskus KE, Reichman JH. Camb university Press NY; 2005:425-456.
48. Bapna JS: 'Pharmaco-economics and Outcomes research in India'. International Society for Pharmacoeconomics and Outcomes Research 2nd Asia-Pacific Conference Shanghai. 6 March 2006
49. Laing R, Waning B, Gray A, Ford N, 'tHoen E: 25 Years of the WHO essential medicines lists: progress and challenges. Lancet 2003:1723-1729.
50. Drummond M: 'ISPOR and the medical device world' ISPOR Asia medical device and diagnostics council forum'. International Society for Pharmacoeconomics and Outcomes Research 2nd Asia-Pacific Conference Shanghai. 6 March 2006
51. Drummond M: 'ISPOR and the medical device world' ISPOR Asia medical device and diagnostics council forum'. International Society for Pharmacoeconomics and Outcomes Research 2nd Asia-Pacific Conference Shanghai. 6 March 2006
52. Global Harmonisation Taskforce [http://www.ghtf.org/information/ information.htm]. (last accessed 20 feb 2006)
53. Maskus KE, Reichman JH: "The Globalisation of private knowledge goods and the privatisation of global public goods" in KE Maskus and JH Reichman 2005 International Public Goods and Transfer of Technology Under a Globalised Intellectual Property regime Cambridge University Press, NY 2005:3-45.
54. Leary VA: The right to health in international human rights law. Health and Human Rights 1994, 1(1):24-32.
55. World Trade Organisation: Declaration on the TRIPS agreement and public health WT/MIN(01)/DEC/2. 20 November 2001
56. UNESCO: Universal Declaration on Bioethics and Human Rights [http://portal.unesco.org/shs/en/ey.php-URLID=1883&URLDO= DOTOPIC&URLSECTION=201.html]. last accessed 12 Dec 2005
57. Cochrane AL: Effectiveness and Efficiency Random Reflections on Health Services London Nuffield Provincial Hospitals Trust 1972.
58. Lopez-Casasnovas, Puig-Junoy: Review of the literature on reference pricing health policy 2000 2000, 54:87-123.
59. Hill SR, Mitchell AS, Henry DA: Problems with the interpretation of pharmacoeconomic analysis: a review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA 2000, 283:2116-2121.
60. Brita Pekarsky Working Paper presented to CGKD 2006.
61. Stocker H, Waitzkin H, Iriart C: 'The Exportation of Managed Care to Latin America,'. New England Journal of Medicine 1999, 340:1131-1136.
62. Kaplan RL: 'Who's Afraid of personal responsibility? Health savings accounts and the future of American health care'. McGeorge Law Review 2005, 36:535-568.
63. US Department of Commerce International Trade Administration: Pharmaceutical Price Controls in OECD Countries. Implications for US Consumers, Pricing, Research and Development and Innovation Washington DC 2004.
64. Blumenthal D, Hsiao W: "Privatisation and its Discontents-The Evolving Chinese Health Care System". New England Journal of Medicine 2005, 353(11):1165-1172.
65. Barr MD: "Medical Savings Accounts in Singapore: A Critical Inquiry". J Health Polit Policy Law 2001, 26:709-712.
66. Will Delaat: PBS Reform for a Healthy Australia. Address by Chairman, Medicines Australia. National Press Club, 3 August 2005 [http://www.medicinesaustralia.com.au/]. viewed 14 February, 2006
67. United Nations: Human Development Report 2005. United Nations Development Programme New York 2005. at 135
68. Foundation for Taxpayer and Consumer Rights [http://www.consumerwatchdog.org/pr/?postld=5512]. last accessed 4 January 2006
69. Moynihan R: US politicians want federal funding to discover cost effectiveness of new drugs. British Medical Journal 2003, 327:642-645.
70. Shiner J: Evidence to Committee on Finance Subcommittees on Health Care and International Trade. United States Senate, Washington 2004.
71. US Department of Commerce International Trade Administration: Pharmaceutical Price Controls in OECD Countries. Implications for US Consumers, Pricing, Research and Development and Innovation Washington DC 2004.
72. The so-called "TRIPS Agreement" is Annex 1C of the 1994 Marrakesh Agreement Establishing the World Trade Organisation. All relevant texts are published by the WTO (on line and in hard-copy with Cambridge University Press 1994) as The Legal Texts: The Results of the Uruguay Round of Multilateral Trade Negotiations.
73. Communication from the United States, Scope and Modalities of Non-Violation Complaints Under the TRIPS Agreement (IP/C/W/194).
74. Professor P Drahos, personal communication 2005.
75. Davies P. Deputy Secretary, Australian Department of Health and Ageing. AUSFTA Conference. Health Impacts [http://www.apec.org.au/docs/ fta04Davies.pdf.]. [last accessed 4 January 2006]
76. Scherer P: Head Health Division. Delegates to the OECD Group on Health[letter] Pharmaceutical Pricing Policy. Organisation for Economic Cooperation and Development. 20 September 2005
77. Canadian Coordinating Office for Health Technology Assessment: Guidelines for economic evaluations of pharmaceuticals: Canada. 1st edition. Ottawa: CCOHTA; 1994.
78. United Kingdom House of Commons Health Committee: The Influence of the Pharmaceutical Industry. London; The Stationery Office Limited 2005 [http://www.publications.parliament.uk/pa/cm200405/cmselect/cmhealth/42/ 4202.htm]. (last accessed 20 April 05).